Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

Alex1710 Apr. 4 at 9:54 PM

$CTXR Very bullish on this stock, revenue of $3.9 M in just one month, 80% margin. Good pipeline. Promising in Relapsed or Refractory Gynecologic Cancers and in High‑Risk Diffuse Large B‑Cell Lymphoma and more. the liquidity and the nasdaq regain compliance are two minors issue.

1 · Reply

BioTechHealthX Apr. 2 at 8:58 AM

$ABEO $CAPR $CTXR $GCTK $REPL Looking for high-upside biotech plays? These small-cap biotech stocks could deliver outsized returns if catalysts align. See which biotech names are trending now. https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-that-could-deliver-1000-returns/

1 · Reply

BioTechHealthX Apr. 2 at 8:27 AM

$ABEO $CAPR $CTXR $GCTK From gene therapy to AI-driven drug discovery, these top 10 biotech stocks are trending now. See which companies are dominating the biotech space today. https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-to-watch-now/

0 · Reply

chuckyry Apr. 1 at 3:37 PM

$CTXR always sell on news as per Lennys game play 🤣🤣

0 · Reply

SweStonk Apr. 1 at 2:51 PM

$CTXR 1 day green 4 days red. Lennys paid pumps always take this lower... Just look at the chart.

0 · Reply

900fix Apr. 1 at 1:46 PM

$CTXR Crash. Another Lenny Pump n Dump.

0 · Reply

focafoca99 Apr. 1 at 1:35 AM

$CTXR nice news today! https://www.rapidticker.com/news/ctxr-sec-filing-3a790f

0 · Reply

Parshu11 Mar. 31 at 8:04 PM

$CTXR only time we see new people in this part of stockwits that are always bullish, is when ctxr has to pay for it. Shit seems like bots honestly.

0 · Reply

infoman333 Mar. 31 at 6:52 PM

$CTXR looks interesting 👀

0 · Reply

hughbeefman69 Mar. 31 at 6:14 PM

$CTXR are we kind of surprised by how not terrible this weird stock/company is doing today? bullish?

1 · Reply

Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development

CTOR

Mar 24, 2026, 8:00 AM EDT - 12 days ago

Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts

CTOR

$Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers$

Mar 10, 2026, 8:47 AM EDT - 26 days ago

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

CTOR

Mar 4, 2026, 9:15 AM EST - 4 weeks ago

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma

CTOR

Feb 24, 2026, 8:00 AM EST - 5 weeks ago

Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program

Feb 13, 2026, 8:00 AM EST - 7 weeks ago

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTOR

Feb 13, 2026, 8:00 AM EST - 7 weeks ago

Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

CTOR

Feb 11, 2026, 8:00 AM EST - 7 weeks ago

Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar

CTOR

Dec 24, 2025, 5:32 AM EST - 3 months ago

Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus

ASTS METC MWG PATH

Dec 23, 2025, 4:30 PM EST - 3 months ago

Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Dec 23, 2025, 4:30 PM EST - 3 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

CTOR

Dec 10, 2025, 4:30 PM EST - 4 months ago

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Dec 9, 2025, 8:30 AM EST - 4 months ago

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

CTOR

Dec 4, 2025, 8:37 AM EST - 4 months ago

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim

CTOR

Dec 1, 2025, 12:00 PM EST - 4 months ago

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)

CTOR

Nov 25, 2025, 8:00 AM EST - 4 months ago

Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting

CTOR

Nov 21, 2025, 8:37 AM EST - 4 months ago

Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration

CTOR

Oct 21, 2025, 4:30 PM EDT - 5 months ago

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025, 8:16 AM EDT - 5 months ago

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

NEUP PCAR

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 17, 2025, 5:00 PM EDT - 6 months ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTOR

Oct 16, 2025, 8:47 AM EDT - 6 months ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTOR

Sep 10, 2025, 4:30 PM EDT - 7 months ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Sep 9, 2025, 8:30 AM EDT - 7 months ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Aug 22, 2025, 8:47 AM EDT - 8 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTOR

Aug 12, 2025, 4:30 PM EDT - 8 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Jul 17, 2025, 4:30 PM EDT - 9 months ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTOR

Jul 16, 2025, 9:15 AM EDT - 9 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTOR

Jul 15, 2025, 8:32 AM EDT - 9 months ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTOR

Jul 8, 2025, 8:34 AM EDT - 9 months ago

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 17, 2025, 8:08 AM EDT - 10 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

Jun 12, 2025, 8:35 AM EDT - 10 months ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 10, 2025, 7:00 AM EDT - 10 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

May 14, 2025, 4:30 PM EDT - 11 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:37 AM EDT - 11 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Apr 1, 2025, 9:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Feb 14, 2025, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Feb 6, 2025, 8:55 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Jan 8, 2025, 8:00 AM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 7, 2025, 8:08 AM EST - 1 year ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

Jan 6, 2025, 7:50 AM EST - 1 year ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTOR

Dec 27, 2024, 5:00 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Nov 25, 2024, 8:03 AM EST - 1 year ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Nov 22, 2024, 9:00 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Nov 18, 2024, 4:05 PM EST - 1 year ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Nov 15, 2024, 1:30 PM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Nov 11, 2024, 8:45 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Aug 12, 2024, 5:28 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Alex1710 Apr. 4 at 9:54 PM

1 · Reply

BioTechHealthX Apr. 2 at 8:58 AM

1 · Reply

BioTechHealthX Apr. 2 at 8:27 AM

0 · Reply

chuckyry Apr. 1 at 3:37 PM

$CTXR always sell on news as per Lennys game play 🤣🤣

0 · Reply

SweStonk Apr. 1 at 2:51 PM

$CTXR 1 day green 4 days red. Lennys paid pumps always take this lower... Just look at the chart.

0 · Reply

900fix Apr. 1 at 1:46 PM

$CTXR Crash. Another Lenny Pump n Dump.

0 · Reply

focafoca99 Apr. 1 at 1:35 AM

$CTXR nice news today! https://www.rapidticker.com/news/ctxr-sec-filing-3a790f

0 · Reply

Parshu11 Mar. 31 at 8:04 PM

$CTXR only time we see new people in this part of stockwits that are always bullish, is when ctxr has to pay for it. Shit seems like bots honestly.

0 · Reply

infoman333 Mar. 31 at 6:52 PM

$CTXR looks interesting 👀

0 · Reply

hughbeefman69 Mar. 31 at 6:14 PM

$CTXR are we kind of surprised by how not terrible this weird stock/company is doing today? bullish?

1 · Reply

drkazmd65 Mar. 31 at 3:48 PM

$CTXR - This company still has a long road ahead of it to regain good standing in the markets and with it's shareholders. However, revenue is always better than no revenue and at least they are actually on a road forward now.

0 · Reply

Rumponstiffskin Mar. 31 at 2:01 PM

$CTXR People always trying to downgrade a company before real pr gets out....

0 · Reply

TwongStocks Mar. 31 at 1:27 PM

$CTOR PR this morning. $CTXR Marketing campaign https://bullseyealerts.com/ctxr-14/

0 · Reply

TwongStocks Mar. 31 at 1:21 PM

$CTOR $CTXR No forward guidance or unaudited sales numbers in the PR. But they state that the Lymphir launch is progressing well. Next ER is due by May 15 (45 days after Mar 31). So we will know by mid-May how the Jan-Mar sales went.

1 · Reply

InvestorRelations_ Mar. 31 at 1:12 PM

$CTXR lets gooo 🤪

0 · Reply

TwongStocks Mar. 31 at 1:12 PM

$CTOR $CTXR Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development https://www.prnewswire.com/news-releases/citius-oncology-provides-commercial-update-on-lymphir-launch-highlighting-early-adoption-and-expanding-clinical-development-302729879.html

0 · Reply

ElowenLun Mar. 31 at 9:52 AM

$CTXR

0 · Reply

ElowenLun Mar. 31 at 9:45 AM

$CTXR

0 · Reply

Cooch23 Mar. 30 at 1:32 AM

$CTXR when r/s

1 · Reply

np_stocks Mar. 28 at 2:26 PM

$CTXR couldn’t agree more.

0 · Reply

SweStonk Mar. 26 at 8:46 PM

$CTOR I knew this was gonna drop but never thought it would be this low this fast. Wonder how many got stuck after $6 run. They would need a miracle only to get back to ~$2 Even more for $6. Guess distribution to $CTXR shareholders wont happen for atleast 4+ years if ever. Not possible for distribution when company risk R/S and if they do a R/S the distribution could trigger another R/S so that would prevent a distribution to happen at all.

1 · Reply

OfficialStocktwitsUser Mar. 26 at 6:56 PM

$CTXR RSI: 39.95, MACD: -0.0180 Vol: 0.08, MA20: 0.82, MA50: 0.80 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Market Cap	19.11M
Revenue (ttm)	0.00
Net Income (ttm)	-37.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	287,000
Avg Vol	615,186
Day's Range	N/A - N/A
Shares Out	22.38M
Stochastic %K	69%
Beta	1.38
Analysts	Sell
Price Target	$6.00